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Abstract
"Dravet syndrome" (DS) previously named severe myoclonic epilepsy of infancy (SMEI), or epilepsy
with polymorphic seizures, is a rare disorder characterized by an early, severe, generalized,
epileptic encephalopathy.
DS is characterized by febrile and afebrile seizures beginning in the 1st year of life followed by
different types of seizures (either focal or generalized), which are typically resistant to antiepileptic
drugs. A developmental delay from the 2nd to 3rd year of life becomes evident, together with
motor disturbances and personality disorders.
Beside the classic syndrome, there are milder cases which have been called severe myoclonic
epilepsy borderline (SMEB).
DS is caused by a mutation in the neuronal sodium channel gene, SCN1A , that is also mutated in
generalized epilepsy with FS+ (GEFS+).
Introduction
Dravet Syndrome (DS) was named after Charlotte Dravet
who described this condition for the first time in 1978 [1]
as severe myoclonic epilepsy, (SME) in a group of intrac-
table epilepsy.
In the classification of ILAE [2] severe myoclonic epilepsy
of infancy (SMEI) is included among " epilepsies and syn-
dromes undetermined as generalized or focal".
Subsequent publications have reported patients with SME
in families with GEFS+ and also the high familial occur-
rence for febrile and afebrile seizures, myoclonic astatic
epilepsy and Lennox-Gastaut syndrome [3,4].
In 2001, Claes et al. [5] considering the presence of febrile
seizures in patients with DS, examined the SCN1A gene,
finding the novo mutations in probands, thus demon-
strating that SCN1A is the main gene responsible for
SMEI.
Other studies have confirmed the mutation of this gene in
most, but not all patients affected. The same mutation has
also been observed in concordant monozygotic twins [6].
In the last classification of Engel [7] SME is called D S and
is included within the epileptic syndrome.
Epidemiology
DS is a rare disorder.
The incidence is 1/40000 [8] o 1/20000 or 30000 [9] in
the general population. Males are more frequently
affected than females (2:1). Among patients with epi-
lepsy, the incidence is 3%-5% in the first year of life and
7% by the age of 3 years [10].
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A family history of epilepsy or febrile seizures is present in
approximately 25% of cases.
A mutated SCN1A gene cannot be identified in approxi-
mately 20% of the patients who fulfil all the diagnostic
criteria of the syndrome. Therefore it is possible that genes
other than SCN1A such as GABAA-receptor gamma 2 sub-
unit might be involved [11].
Clinical findings and progression
Symptoms begin in the first year of life, or more often in
the first six months, with tonic-clonic seizures almost
always triggered by fever in an otherwise normal child. For
this reason, the onset of the syndrome may be indistin-
guishable from febrile seizures.
A significant number of DS patients has a family history
of seizures disorders or febrile seizures with phenotypes
consistent with the GEFS+ spectrum, but the first febrile
seizures episode is usually protracted. Between the 1st and
4th year of life additional febrile and afebrile seizures
appear. The afebrile seizures are more frequently unilat-
eral, tonic clonic, or secondary generalized, evolving later
on towards other types of epilepsy including myoclonic,
atypical absence, and atonic seizures, alternating partial
seizures and convulsive status epilepticus. Recurrent sta-
tus epilepticus which is always provoked by fever is a fre-
quent event. Myoclonic seizures are not invariably present
at onset. In the majority of cases, convulsive episodes have
a focal origin. Generalized seizures are atypical absence
with 2-3,5 Hz spike and waves discharges. Tonic seizures
are very rare. Seizures, and in particular myoclonic sei-
zures, occur very frequently during the first 4-5 years of
life and are extremely drug resistant [12]. Some drugs such
carbamazepine, lamotrigine, phenobarbital and pheni-
toin can exacerbate epilepsy.
Epilepsy has a tendency to improve over time.
Early psychomotor development is normal before convul-
sions starts, but developmental stagnation occur in the
second year of life. Later a regression becomes evident,
accompanied by hyperactivity, language deterioration
and mental retardation and subsequently by pyramidal
signs.
Some patients with DS show a " milder type" with less
severe myoclonic epilepsy, less frequent tonic clonic sei-
zures or status epilepticus, milder mental retardation and
only transient ataxia (severe myoclonic epilepsy border-
line SMEB).
DS is still a clinical diagnosis and the absence of a muta-
tion in the SCN1A gene in symptomatic patients does not
exclude the diagnosis.
Clinically, DS must be suspected in each otherwise nor-
mal child, with long lasting FS starting in the first years of
life, followed by different type of afebrile seizures and
neurodevelopment impairment. In these cases mutations
in the SCN1A gene must be sought.
Today DS, the less severe borderline forms (SMEB) and
GEFS+, can be considered as a continuum of the same
condition [13,14].
The cognitive development of children with DS is con-
stantly compromised. In the 1st year of life, patients are
completely normal but in the 2nd year a slowing or a stag-
nation in psychomotor development is evident. In this
period, the presence of behavioural disorders manifesting
more often with hyperactivity and less frequent with autis-
tic traits are also noted. Severe mental retardation is evi-
dent around the 5th year in almost all children, affecting
all functional area. Sometimes in coincidence with a
decrease in frequency of the epileptic seizures, the cogni-
tive ability improves slghtly. In the first years of the dis-
ease, the motor and visuomotor functions are better
preserved than language skills that are constantly compro-
mised.
The aetiology of the cognitive and behavioural distur-
bances is not clear.
Risk factor for the presence of mental retardation are the
onset of the epilepsy in the 1st year of life, high recurrence
of seizures, status epilepticus and the presence of addi-
tional minor seizures.
Other neurological symptoms, such as progressive ataxia
and pyramidal signs, give these patients a characteristic
aspect.
EEG findings
At the beginning of the symptoms the EEG is usually nor-
mal. With the recurrence of febrile and afebrile seizures,
abnormalities become evident consisting of generalized,
focal or multifocal anomalies, such as multifocal spikes,
spike and waves, polyspike and waves discharges and a
slowing of background activity. The intermittent light
stimulation can be positive even before 1 year. Photosen-
sitivity is not a constant feature during the course of the
disease but in SMEI patients there is a photosensitivity
spectrum because this response can persist and in some
patients can be used as self-stimulation [15].
In general paroxysmal activity tends to disappear while
awake but is prominent during sleep.
Ictal EEG anomalies, are suggestive of the syndrome and
have been reported by Dravet e coll. [16] with video - pol-Italian Journal of Pediatrics 2009, 35:27 http://www.ijponline.net/content/35/1/27
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ygraphic EEG recordings. The EEG discharge is bilateral
but according to three modalities: 1) bilateral abnormali-
ties from onset as slow spike or slow waves followed by a
brief attenuation, 2) initially bilateral abnormalities
becoming asymmetric, 3) bilateral and symmetric at their
onset. The postictal EEG shows diffuse flattening or slow-
ing.
Moreover, the peculiar clinical seizures and EEG features
still not permit the real nature of this syndrome if multi-
focal or generalized.
Brain imaging
Neuroimaging studies (CT and MRI), do not show any
typical brain lesions even if brain abnormalities may exist
[17]
In a recent review by Striano and coll. [18] on 58 brain
MRIs in patients with SME, 22,4% of the patients showed
abnormal findings consistent with cortical brain atrophy,
cerebellar atrophy, hippocampal sclerosis, focal cortical
dysplasia and ventricular enlargement. The authors con-
cluded that the observed abnormal MRIs occurred more
frequently in 39,15% of the patients without SCN1A
mutation compared to 11,4% of those carrying a SCN1A
mutation. These findings, if confirmed do not support the
association in between prolonged febrile seizures and hip-
pocampal sclerosis as previously reported by Siegler [19]
in a retrospective study in 10 of 14 patients.
Diagnosis
DS is still a clinical diagnosis that is mainly based on sei-
zure history, clinical aspects, neurologic examination,
EEG pattern and a long observation. Subsequently, DNA
analysis with the evaluation of the SCN1A gene can con-
firm the diagnosis in the majority of cases.
In Appendix 1 are reported some diagnostic criteria. Cur-
rently, the diagnosis is suspected and performed earlier
than before, because of the possibilities offered by molec-
ular diagnosis.
Relationship between DS and GEFS+
DS shares the same gene with GEFS+, wich was described
by Scheffer and Berkovic in 1997 [3] in a large Australian
family with epilepsy. It is an autosomal-dominant disor-
der in which a peculiar phenotype of febrile seizures
(called FS+) has been demonstrated. These seizures start
early and persist beyond 6 years of age. In the affected
family coexist members with FS, FS+ and various types of
afebrile seizures, such as GTCS, absence, atonic, myo-
clonic and also partial seizures. The afebrile seizures usu-
ally begin in childhood a continuum with febrile seizures
being characteristic, occurring often after a variable sei-
zure-free period. The prognosis is relatively benign with-
out severe neurologic impairment. Affected members can
exhibit more severe epileptic syndromes such as myo-
clonic astatic epilepsy (MAE), L G, and rarely DS.
GEFS+ is a heterogeneous genetic syndrome caused by
more genes [3,11,13]. The first gene is SCN1B located on
19q 13.1 encoding the beta 1 subunit of the neuronal
voltage- gated sodium channel. A second gene map in the
region 2q21-q33 on SCN1A as in DS and finally a third
SCN2A gene is located on 2q21-q23 encoding the alfa 2
subunit of the voltage-gated sodium channel.
Baulac et al [20] localized another gene of the gamma
aminobutyric acid receptor (GABA A) on chromosome
5q34 but only few patients show this abnormality [21]
Differential diagnosis
The differential diagnosis must consider simple febrile sei-
zures, benign myoclonic epilepsy, LGS, MAE and the pro-
gressive myoclonic epilepsy.
Simple febrile seizures onset is mainly between 6 and 18
months, with tonic-clonic fits lasting < 15 minutes. The
onset of FS in DS is within the first 6 months, they are
more often unilateral, clonic and long lasting as febrile
status.
Benign myoclonic epilepsy is accompanied by generalized
spike and waves in the EEG and the myoclonic attacks are
the only ictal manifestation. The neurological status is
normal.
LGS starts later without FS with tonic attacks which are
not evident in DS. The EEG shows diffuse 2/3 Hz spikes
and waves. The differentiation between DS and MAE is
very difficult, but in DS the drop attacks are not recurrent.
Progressive myoclonic epilepsies can be excluded because
of the progressive worsening of symptoms and of the pres-
ence of metabolic dysfunction signs and progressive
encephalopathy.
A skin biopsy in order to exclude ceroidolipofuscinosis
(NCL) or a mitochondrial disease is often performed in
patients with DS.
Genetics
DS is a channellopaty caused by a mutation of the SCN1A
gene with an average prevalence of 80% and ranging from
40% to 100% of the patients [22]. This difference is not
explained by the ethnic origin, because it is present in
Europe, Japan, Australia and South America, but perhaps
is due to a lack of strict diagnostic criteria in the selection
of patients. In Japan, the rate of mutation in SMEI patients
is 77%-82%, in French, Italian, Australian and Canadian
populations the incidence is much lower and only 35% of
the cases are mutated.Italian Journal of Pediatrics 2009, 35:27 http://www.ijponline.net/content/35/1/27
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SCN1A is found mutated in about 5% to 10% of GEFS+
patients.
The same mutation has also been found in SMEB and in
single patients with severe myoclonic epilepsy and infan-
tile spasms (IS) [23]. The SCN1A gene
Is located within a cluster of three sodium channel genes
including SCN2A and SCN3A on chromosome 2q24. The
beta subunit, SCN1B, was the first molecular link with
GEFS+ [24]. Missense mutation in the alfa subunit,
SCN2A, are associated with (BFNS) benign familial neo-
natal infantile seizures [25].
The SCN1A gene has a dominating role in the pathogene-
sis of DS with over 100 different mutations. The majority
of these mutations are de novo (88%) but several are
recurrent [26]. These mutations are spread throughout the
entire protein with some clusters in the C-terminal and N-
terminal ends and in segment 5-6 of the first 3 domains.
SCN1A is the most clinically relevant epilepsy gene.
A few cases of DS children show a SCN1A microdeletion
associated with mild dysmorphic traits and increased sei-
zure resistance. This pattern has been called Dravet syn-
drome plus [27,28].
Other genetic or environmental modifiers or mosaics in
parents as in other genetic diseases can be considered.
In Table 1 are reported the genes for DS and GEFS+.
Prognosis
The prognosis is unfavourable in the majority of cases. All
patients have drug resistant seizures that tend to persist
throughout life. FS stop and the other seizures became less
evident in the 2nd decade of life. The EEG anomalies are
persistent.
Myoclonic seizures are very resistant to therapy and the
period of the high recurrence of these seizures is associ-
ated with more severe neuropsychological impairment.
Mental retardation is constant together with other neuro-
logical symptoms, like ataxia and spasticity. The convul-
sions are long lasting, status epileptics and the high
recurrence of the episodes, particularly in the first years of
life, deteriorate the brain function contributing to the
neurological problems of these patients.
Treatment
It is not know why this condition is so strongly drug resist-
ant.
Some drugs such as phenobarbital, phenytoin, car-
bamazepina and lamotrigina may exacerbate seizures.
Valproate, clobazam and topiramate, are the drugs most
frequently used with some result [12,14]. Stiripentol (not
approved in US) is considered to be useful. Alternative
therapies such the ketogenic diet, have been tried, but the
results are controversial [29].
Personal observations
In the last 6 years, we have evaluated 6 patients with a
clinical picture compatible with the diagnosis of DS.
Symptoms were severe in 5 patients consisting of severe
hypotonia, dysmorphic features, and seizures since birth;
a deletion of the entire SCN1A gene was found in 1 case
with secondary generalization in another. Mutations in
exons 20,21 and 23 of the SCN1A gene were found in 4
patients.
In our experience the two patients with deletions of the
gene had clinically more severe epilepsy and both had
dysmorphic features, severe microcephaly and marked
psychomotor retardation.
Hyperactivity and attention deficit disorder, autistic traits,
language disturbances and mental retardation were con-
stantly present in all patients and persisted until adoles-
cence.
Conclusion
DS is an early infantile encephalopathy in which it is now
possible to document the genetic background in a sub-
stantial number of cases.
Since the same genetic background has been demon-
strated in other epileptic syndromes, it is possible that this
condition is part of an epileptic continuum
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Appendix 1
Diagnosis of DS
Multiple seizures, frequently provoked by fever before 1
year
Table 1: Sodium channel Gene for DS and GEFS+
Gene Epilepsy syndrome
SCN1A GEFS+
SMEI (Dravet syndrome)
SCN2A GEFS+
BFNIS (benign familial neonatal infantile seizures)
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Unilateral or generalized clonic or tonic clonic seizures
Resistance to therapy
Normal development before seizure onset
Development delay at the age of 2 years
Normal interictal EEG in the early stages
Normal neurologic examination
Normal metabolic work up
Status epilepticus
Myoclonic seizures
Afebrile partial or secondary generalized seizures
Seizures provoked by fever after the age of 5
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